top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance


07/07/2026







ITM‑11 significantly outperforms everolimus in advanced GEP‑NETs with superior efficacy and safety (Ref)


ITM announced that primary results from its Phase 3 COMPETE trial were published in The Lancet, showing that investigational ¹⁷⁷Lu-edotreotide (ITM-11; SSTR2-targeted peptide receptor radionuclide therapy) significantly improved progression-free survival and response rates vs everolimus in Grade 1/2, somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) patients.


The trial enrolled 309 patients across 49 sites and met its primary endpoint with a favorable safety profile for ITM-11


  • Median PFS: 23.9 mos (ITM-11) vs 14.1 mos (everolimus); HR 0.67, p=0.022


  • Objective response rate: 22% vs 4% (central review), p<0.0001


  • Grade 3/4 TRAEs: 18% vs 40%


  • Common side effects for ITM-11: diarrhea and nausea (36% each), asthenia (33%)


  • 57.6% of patients had pancreatic NETs, an area with limited treatment options


Upcoming milestones:


  • ITM-11 is currently under US FDA regulatory review


  • Long-term follow-up: patients will be monitored up to 5 years for survival/safety data



bottom of page